Pay in 4 interest-free payments of $5.79 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
The increase in GLP-1 usage has an impact across every category of the food and beverage industry
No patients receiving GLP-1 RAs were excluded due to loss of follow-up, while 8 patients (0.2%) who did not receive GLP-1 RAs were excluded for this reason (Supplemental Table 3)
For there to be cost-effectiveness in saving money on claims related to cardiovascular disease, these drugs for weight loss should be priced at $7,500 to $9,800 annually
A new analysis of data from the SELECT trial shows that semaglutide, a GLP-1 receptor agonist, provides a clear cardiovascular protective effect in people with overweight or obesity and already established cardiovascular disease, even when they do not have diabetes
[PMID: 20181080] 17
US$ 29.57
US$ 26.28
US$ 27.43
US$ 28.19
US$ 28.92
US$ 24.44
US$ 22.87
US$ 29.50
US$ 27.35
US$ 29.17
US$ 20.49
US$ 22.05
US$ 28.98
US$ 26.04
US$ 26.72
US$ 25.66
